A Phase 2, Open-Label, Randomized, Controlled, Dose Cohort, Pharmacokinetic and Safety Study of Oral Lofexidine in Neonates Experiencing Opioid Withdrawal Due to Intrauterine Exposure to Opioids
Latest Information Update: 28 Sep 2024
At a glance
- Drugs Lofexidine (Primary)
- Indications Opioid-related disorders
- Focus Pharmacokinetics
- Sponsors US WorldMeds
- 19 Sep 2024 Planned End Date changed from 1 May 2026 to 1 Dec 2026.
- 19 Sep 2024 Planned primary completion date changed from 1 May 2024 to 1 Dec 2024.
- 16 Oct 2023 Status changed from not yet recruiting to recruiting.